Navigation Links
Allan J. Collins, M.D., to join NxStage as Senior Medical Advisor
Date:8/12/2014

LAWRENCE, Mass., Aug. 12, 2014 /PRNewswire/ -- NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, announced today that Allan J. Collins, M.D., a recognized worldwide leader in the field of nephrology, will join the Company as Senior Medical Advisor and head the Company's Medical Advisory Board. 

Dr. Collins is a Professor of Medicine at the University of Minnesota.  He is the Director of the Chronic Research Disease Group, an interdisciplinary biomedical research group committed to the investigation of chronic illnesses to improve public health, and as part of this, served as the coordinating center for the United States Renal Data System (USRDS) and its Annual Data Report from 2000 through 2014.  Dr. Collins was presented the Distinguished Service Award by the National Kidney Foundation (NKF) in 2003, and served as the President of the NKF from 2006 through 2008.  He has over 200 clinical publications, and is an invited lecturer worldwide.  Dr. Collins continues his clinical practice with dialysis patients under his care as the Medical Director for the DaVita Coon Valley Dialysis Unit.  Dr. Collins has served as a member of the NxStage® Scientific Advisory Board for the last 4 years.

"I believe fresh approaches with innovative technologies are essential to address the long intractable problems we've seen with chronic dialysis therapy, particularly cardiovascular issues and low quality of life," said Collins. "The talented NxStage team has substantially advanced home dialysis therapies to date, and will continue to do so on a broader scale with future innovations.  It will be a pleasure to help advance the care of the dialysis population by advising NxStage on data-driven analytics and communications while leading a world-class team of medical advisors."

Dr. Collins will assume the leadership role from Dr. Alan Hull, who has headed the NxStage Medical Advisory Board since 2004.

"We have always actively sought the best scientific counsel in our ongoing mission to invent, improve and inspire," said Joe Turk, NxStage's President. "We thank Dr. Hull for all of his years of commitment, and we are delighted that Dr. Collins will now be collaborating so closely with NxStage going forward.  NxStage, and future patients for our life-changing technologies, will benefit from the ongoing contributions of Dr. Collins' tremendous knowledge and leadership skills."

About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media contact:
Meredith D'Agostino
mdagostino@451marketing.com
516-884-7162

Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO


'/>"/>
SOURCE NxStage Medical Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
2. HeartWare International Announces Appointment Of Katrin Leadley, M.D., As Chief Medical Officer
3. Champions Oncology Names Angela Davies, M.D., Chief Medical Officer
4. Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., As Chief Medical Officer
5. LipoScience Announces Appointment Of William Cromwell, M.D., As Chief Medical Officer
6. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
7. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
8. Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors
9. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
10. Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs
11. Fuisz llc Announces Induction of Richard C. Fuisz, M.D., into Georgetown Universitys 1789 Society.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  A new survey ... that Medicare,s Competitive Bidding Program (CBP) significantly reduced beneficiary ... The lack of choice forces beneficiaries to switch to ... health consequences. AADE,s survey is the ... and others pointing out the inherent problems with the ...
(Date:3/27/2017)... YORK , March 27, 2017 FinancialBuzz.com News ... According to a new ... North America , grew 34 percent to $6.7 billion and ... rate of (CAGR) over the next five years, from $6.7 billion in ... of Americans that will be able to purchase cannabis without a doctor,s ...
(Date:3/27/2017)... Mass. , March 27, 2017   Pulmatrix, Inc ... inhaled therapies to address serious pulmonary diseases, today announced that ... fungal disease, cystic fibrosis and asthma to its Scientific ... Richard B. Moss , MD, former ... Director of the Cystic Fibrosis Center at Stanford University, and ...
Breaking Medicine Technology:
(Date:3/27/2017)... Arlington, VA (PRWEB) , ... March 27, 2017 ... ... version 3.0 was transitioned to the OSEHRA popHealth Community in 2014. ... Steering Work Group and the Developer Open Source Project Group. OSEHRA Organizational Member ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... training, today announced the launch of a new research study, The Business Readiness ... needed to execute that strategy, and the actual success of achieving individual and ...
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... According ... with prostate cancer, including all stages, is more than 95%. Once the cancer spreads ... to less than 30%. To find out how to avoid this latter group, tune ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency ... on Monday, April 3rd to commemorate the two-year anniversary of the facility. The ... to celebrate two great years while also familiarizing themselves with the facility. , ...
Breaking Medicine News(10 mins):